176 related articles for article (PubMed ID: 26364797)
21. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
Verstovsek S; Kiladjian JJ; Vannucchi AM; Mesa RA; Squier P; Hamer-Maansson JE; Harrison C
Cancer; 2023 Jun; 129(11):1681-1690. PubMed ID: 36840971
[TBL] [Abstract][Full Text] [Related]
22. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry.
Góra-Tybor J; Gołos A; Mikulski D; Helbig G; Sacha T; Lewandowski K; Niesiobędzka-Krężel J; Bieniaszewska M; Wysogląd H; Grzybowska-Izydorczyk O; Seferyńska I; Sobas M; Czyżewska M; Michalska A; Sawicki W; Mazur M; Hus M; Bodzenta E; Olszewska-Szopa M; Włodarczyk M; Patkowska E; Świstek W; Jamroziak K
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e19-e26. PubMed ID: 36396583
[TBL] [Abstract][Full Text] [Related]
24. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
[TBL] [Abstract][Full Text] [Related]
25. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
[TBL] [Abstract][Full Text] [Related]
26. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Mead AJ; Milojkovic D; Knapper S; Garg M; Chacko J; Farquharson M; Yin J; Ali S; Clark RE; Andrews C; Dawson MK; Harrison C
Br J Haematol; 2015 Jul; 170(1):29-39. PubMed ID: 25824940
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
28. Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.
Ayala R; Fernández RA; García-Gutiérrez V; Alvarez-Larrán A; Osorio S; Sánchez-Pina JM; Carreño-Tarragona G; Álvarez N; Gómez-Casares MT; Duran A; Gorrochategi J; Hernández-Boluda JC; Martínez-López J
EJHaem; 2023 May; 4(2):401-409. PubMed ID: 37206258
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project.
Coltro G; Sant'Antonio E; Palumbo GA; Mannelli F; De Stefano V; Ruggeri M; Elli EM; Zanotti R; Borsani O; Bertozzi I; Duminuco A; Betti S; Carli G; Cavalca F; Tanasi I; Rumi E; Randi ML; Garibaldi B; Loscocco GG; Guglielmelli P; Vannucchi AM
Cancer Med; 2023 Apr; 12(7):8166-8171. PubMed ID: 36708083
[TBL] [Abstract][Full Text] [Related]
30. Practical management of patients with myelofibrosis receiving ruxolitinib.
Harrison C; Mesa R; Ross D; Mead A; Keohane C; Gotlib J; Verstovsek S
Expert Rev Hematol; 2013 Oct; 6(5):511-23. PubMed ID: 24083419
[TBL] [Abstract][Full Text] [Related]
31. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.
Komatsu N; Kirito K; Shimoda K; Ishikawa T; Ohishi K; Ohyashiki K; Takahashi N; Okada H; Amagasaki T; Yonezu T; Akashi K
Int J Hematol; 2017 Mar; 105(3):309-317. PubMed ID: 27832516
[TBL] [Abstract][Full Text] [Related]
32. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
Martí-Carvajal AJ; Anand V; Solà I
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010298. PubMed ID: 25860512
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.
Soyer N; Ali R; Turgut M; Haznedaroğlu İC; Yılmaz F; Aydoğdu İ; Pir A; Karakuş V; Özgür G; Kiş C; Ceran F; İlhan G; Özkan M; Aslaner M; İnce İ; Yavaşoğlu İ; Gediz F; Sönmez M; Güvenç B; Özet G; Kaya E; Vural F; Şahin F; Töbü M; Durusoy R; Saydam G
Turk J Med Sci; 2021 Jun; 51(3):1033-1042. PubMed ID: 33315343
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
Wade R; Rose M; Neilson AR; Stirk L; Rodriguez-Lopez R; Bowen D; Craig D; Woolacott N
Pharmacoeconomics; 2013 Oct; 31(10):841-52. PubMed ID: 23996108
[TBL] [Abstract][Full Text] [Related]
35. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
[TBL] [Abstract][Full Text] [Related]
36. Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.
Davis KL; Côté I; Kaye JA; Mendelson E; Gao H; Perez Ronco J
Adv Hematol; 2015; 2015():848473. PubMed ID: 26635878
[TBL] [Abstract][Full Text] [Related]
37. A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort.
Tavares R; Souza CA; Paley C; Bouard C; Tiwari R; Pasquini R
Hematol Transfus Cell Ther; 2020; 42(1):46-53. PubMed ID: 31235325
[TBL] [Abstract][Full Text] [Related]
38. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Cervantes F; Vannucchi AM; Kiladjian JJ; Al-Ali HK; Sirulnik A; Stalbovskaya V; McQuitty M; Hunter DS; Levy RS; Passamonti F; Barbui T; Barosi G; Harrison CN; Knoops L; Gisslinger H;
Blood; 2013 Dec; 122(25):4047-53. PubMed ID: 24174625
[TBL] [Abstract][Full Text] [Related]
39. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
40. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Vergis N; Phillips R; Cornelius V; Katsarou A; Youngstein T; Cook L; Willicombe M; Pilay C; Shturova T; Almonte M; Charania A; Turner R; Kon OM; Cooke G; Thursz M; Cherlin S; Wason J; Milojkovic D; Innes AJ; Cooper N
Trials; 2021 Apr; 22(1):270. PubMed ID: 33845867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
